v3.26.1
Summary of Significant Accounting Policies - Summary of Segment Reconciliation (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]        
Total research and development $ 5,915 $ 11,580 $ 12,680 $ 22,057
Total selling, general and administrative 3,804 3,318 9,930 7,332
Salaries and staff costs        
Segment Reporting [Line Items]        
Total research and development 1,847 2,134 3,591 4,103
Total selling, general and administrative 915 849 3,844 1,775
Stock-based compensation        
Segment Reporting [Line Items]        
Total research and development 470 672 788 1,187
Total selling, general and administrative 450 1,011 1,792 1,861
Clinical trials, outside services, and lab supplies        
Segment Reporting [Line Items]        
Total research and development 3,162 8,306 7,422 15,803
Outside services and professional fees        
Segment Reporting [Line Items]        
Total selling, general and administrative 2,009 1,062 3,438 2,860
Facilities and other        
Segment Reporting [Line Items]        
Total research and development 436 468 879 964
Total selling, general and administrative $ 430 $ 396 $ 856 $ 836